Spunoleucel

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Cell
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Cell
www.ebi.ac.uk
Drug name
Spunoleucel
www.ebi.ac.uk

  • allogeneic multi virus specific t lymphocytes targeting respiratory syncytial virus rsv influenza parainfluenza virus piv and human metapneumovirus hmpv
  • Allogeneic Multi-Virus Specific T Lymphocytes Targeting Respiratory Syncytial Virus (RSV), Influenza, Parainfluenza Virus (PIV), and Human Metapneumovirus (hMPV)
  • alv 106
  • ALV-106
  • alv106
  • ALV106
  • alvr106
  • ALVR106
  • alvr106 is a novel virus specific cell based therapy to treat four respiratory viral infections that are a serious cause of morbidity and mortality in immunocompromised patients alvr106 is under development to treat four respiratory viral infections respiratory syncytial virus influenza parainfluenza virus and human metapneumovirus that are common and of significant clinical concern in immunocompromised patients including those who have undergone hematopoietic stem cell transplantation solid organ transplantation as well as in vulnerable elderly and pediatric populations
  • ALVR106 is a novel virus-specific cell-based therapy to treat four respiratory viral infections that are a serious cause of morbidity and mortality in immunocompromised patients. ALVR106 is under development to treat four respiratory viral infections (respiratory syncytial virus, influenza, parainfluenza virus and human metapneumovirus) that are common and of significant clinical concern in immunocompromised patients, including those who have undergone hematopoietic stem cell transplantation, solid organ transplantation, as well as in vulnerable elderly and pediatric populations
  • ALVR106 is a polyclonal (CD4+ and CD8+) virus-specific T cell product containing cells that are reactive against four viruses (RSV, Influenza, PIV, and hMPV). The cells are derived from peripheral blood mononuclear cells (PBMCs) from donors seropositive for all four of these viruses
  • alvr106 is a polyclonal cd4 and cd8 virus specific t cell product containing cells that are reactive against four viruses rsv influenza piv and hmpv the cells are derived from peripheral blood mononuclear cells pbmcs from donors seropositive for all four of these viruses
  • alvr106 is comprised of both cd8 and cd4 virus specific t cells capable of recognizing actively replicating virus infected cells proliferating in response to antigenic stimulation and mediating antiviral effects including the production of cytokines and effector molecules killing of infected cells in patients with infections diseases associated with the target viruses
  • ALVR106 is comprised of both CD8+ and CD4+ virus-specific T cells capable of recognizing actively replicating virus-infected cells, proliferating in response to antigenic stimulation and mediating antiviral effects including the production of cytokines and effector molecules, killing of infected cells in patients with infections/diseases associated with the target viruses
  • monovalent (RSV) unlicensed comparator
  • spunoleucel
  • Spunoleucel
  • spunoleucel [INN]
  • SPUNOLEUCEL [USAN]
  • spunoleucel inn
  • spunoleucel usan

ChEMBL ID
CHEMBL6068442
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • EVQ94BW5G4

First in class
No
Orphan designation
No

Investigated indications

  • Condition
    Respiratory Tract Infections
    Highest recorded phase
    1
    Condition identifier
    MONDO:0024355
    Subject identifier
    D012141

  • Condition identifier
    MONDO_0001577
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0005812
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0024355

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

Related records

Trials (12)

In development for (1)